The MarketWatch News Department was not involved in the creation of this content. MONTREAL, Nov. 13, 2025 /CNW/ - Myeloma Canada welcomes the Canadian Drug Agency's (CDA) two positive recommendations ...
Toronto, Ontario--(Newsfile Corp. - November 13, 2025) - Telo Genomics Corp. (TELO:CA) (OTCQB: TDSGF) ("Telo" or the "Company"), a leader in diagnostic and prognostic innovation through its ...
Caring for someone with multiple myeloma can be challenging on many levels. The person who has just been diagnosed may look to you for information to help them better understand the disease to ...
J&J : Canada Approves CARVYKTI For Relapsed Or Refractory Multiple Myeloma After 1-3 Prior Therapies
(RTTNews) - Johnson & Johnson (JNJ) said that Health Canada has issued a Notice of Compliance for CARVYKTI (ciltacabtagene autoleucel) for the treatment of adult patients with multiple myeloma who ...
Real-world treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A retrospective chart study. Most common treatment ...
Multiple myeloma – a rare form of blood cancer – is usually found in people 65 and older. While it’s rare in young adults, a small percentage of people 19-40 also have the disease. Only 10% of people ...
No two cancers are the same. While most people know about cancer, when you get down to the disease level, each type is unique. Take blood cancers, for example: leukemia, lymphoma, and multiple myeloma ...
When you have multiple myeloma, infections are something you’ll need to watch out for. The disease and its treatment make infections more likely. If you get an infection, it’s also more likely to get ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results